Acorda Rebuffed by U.S. Supreme Court Over Ampyra Patents
(Bloomberg) -- The U.S. Supreme Court rebuffed Acorda Therapeutics Inc.'s bid to revive patents on its top-selling multiple sclerosis drug Ampyra.
Trade groups for the drug and biotechnology industries had urged the court to take up the case, saying an appeals court ruling that invalidated Acorda's patents harms incentives to develop new medicines or explore new uses for older drugs.
The patents Acorda sought to revive would have barred competition to Ampyra from low-cost generic drugs until at least 2025. An earlier patent licensed by the company expired in 2018.
Ampyra accounted for nearly all of Ardsley, New York-based Acorda's $471 million in sales last year.
At issue in the lawsuit was when a drug's commercial success can be used to overcome legal challenges that claim its patents are invalid.
Patent challenges, particularly over pharmaceuticals, often rest on the idea that an invention was an obvious variation of known ideas. To illustrate that their patented inventions are unique, drugmakers point to the success of their medicines, failures by others, or evidence that the invention met a long-felt need.
No Incentive
Those arguments have less weight, the U.S. Court of Appeals for the Federal Circuit ruled, when earlier patents exist that blocked others from developing a competing product. There's no incentive for competitors to conduct research, the court said, when they wouldn't be able to sell a product because of the older patent.
The decision was hailed by those who say drugmakers tweak their medicines or develop new uses to get a second generation of patent exclusivity and block competition from generics. The practice, known as “evergreening,” has been the subject of congressional hearings aimed at limiting pharmaceutical patent abuses.
The active ingredient of Acorda's Ampyra, dalfampridine, was first discovered more than a century ago and had been marketed as a bird poison. It initially wasn't approved for human use because it may cause seizures, though researchers first began testing it for neurological diseases in the 1970s.
The Irish biotech company Elan Corporation Plc obtained a patent in the late 1990s for a sustained-release version of the drug to treat diseases including multiple sclerosis.
‘Unexpected Breakthrough'
After failing to develop a drug, Elan licensed the patent to Acorda, which conducted years of research before what it called an “unexpected breakthrough” that led to regulatory approval for Ampyra in 2010.
Acorda's patents cover a dosing regimen that helps MS patients walk without causing seizures.
In a 2-1 ruling, Circuit Judge Richard Taranto said the dosing regimen would have been obvious to researchers before 2004, when Acorda sought its patents. The earlier patent it had licensed from Elan kept others from doing their own research, the judge said.
“Acorda's exclusive license to Elan's patent enabled Acorda to dominate research in that field in the ensuing years,” generic-drug makers Teva Pharmaceutical Industries Ltd., Mylan NV and Hikma Pharmaceuticals Plc's Roxane Labs said in opposing Acorda's Supreme Court petition.
The case is Acorda Therapeutics Inc. v. Roxane Laboratories Inc., 18-1280.
To contact the reporter on this story: Susan Decker in Washington at sdecker1@bloomberg.net
To contact the editors responsible for this story: Jon Morgan at jmorgan97@bloomberg.net, Laurie Asséo, Ros Krasny
©2019 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.